Genomics Collaboration, R&D, and Licensing Deals Analysis Report 2024 with Directory of 948 Agreements Signed Since 2016
07 mai 2024 07h14 HE
|
Research and Markets
Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Genomic Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Genomic Collaboration and Licensing...
Transgene et NEC présentent les premiers signes de bénéfice clinique de leur vaccin individualisé contre le cancer, TG4050, dans les cancers de la tête et du cou à l’AACR 2024
09 avr. 2024 11h45 HE
|
Transgene S.A.
Les nouvelles données immunologiques de Phase I confirment la forte immunogénicité de TG4050 dans le traitement adjuvant des cancers de la tête et du cou.Tous les patients traités sont encore en...
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
09 avr. 2024 11h45 HE
|
Transgene S.A.
Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of...
Viral Vector and Plasmid DNA Technologies Market Outlook 2024-2028: Innovations, Technological Advances and Product Launches from Leading Companies
05 avr. 2024 04h02 HE
|
Research and Markets
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Viral Vector and Plasmid DNA: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for...
Transgene et NEC étendent leur collaboration et poursuivent ensemble le développement clinique de TG4050, un vaccin thérapeutique individualisé contre le cancer
08 janv. 2024 11h45 HE
|
Transgene S.A.
Transgene et NEC prévoient de lancer, en 2024, une extension de l’étude randomisée de Phase I en essai randomisé de phase I/II pour continuer à démontrer le potentiel de TG4050 comme traitement...
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
08 janv. 2024 11h45 HE
|
Transgene S.A.
Transgene and NEC plan to start an extension of the randomized Phase I trial into a randomized Phase I/II study in 2024 to further demonstrate the potential of TG4050 as an adjuvant treatment of...
Gene Therapy Market to hit USD 44.5 billion by 2032, says Global Market Insights Inc.
07 août 2023 17h30 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Gene Therapy Market size is expected to be worth USD 44.5 billion by 2032. The growing adoption of personalized medicine is generating...
Unlocking New Frontiers in Malignancy Treatment: Cell Therapy Clinical Activity and Process Automation Research Report 2023
03 août 2023 07h43 HE
|
Research and Markets
Dublin, Aug. 03, 2023 (GLOBE NEWSWIRE) -- The "Cell Therapy Clinical Activity and Process Automation" report has been added to ResearchAndMarkets.com's offering. Cell therapy, a revolutionary...
Global Cloning & Mutagenesis Market Report 2023: Increasing Research and Development Activities in Cancer and Other Chronic Disorders Fuels Growth
18 avr. 2023 11h58 HE
|
Research and Markets
Dublin, April 18, 2023 (GLOBE NEWSWIRE) -- The "Cloning & Mutagenesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Gene Type (Standard v/s...
Global Gene Therapy Market Report 2023: Major Players Include Novartis, Bluebird Bio, Spark Therapeutics, Audentes Therapeutics and Voyager Therapeutics
06 avr. 2023 05h13 HE
|
Research and Markets
Dublin, April 06, 2023 (GLOBE NEWSWIRE) -- The "Gene Therapy Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists, marketers and...